GlassScriptPhysician profile
Disha K Narang
NPI 1235426230
$140,750.53
in general payments reported to CMS, 2019-2025
12 companies · $82K in 2025
The $82K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,596 · 2021: $3,419 · 2022: $157 · 2023: $568 · 2024: $53K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Travel and Lodging: $18K · Consulting Fee: $5,590 · Food and Beverage: $4,652 · Gift: $59.40 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,274.94 |
| Travel and Lodging | $17,969.49 |
| Consulting Fee | $5,590.00 |
| Food and Beverage | $4,652.11 |
| Gift | $59.40 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $96,809.93 | 2023-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $37,830.25 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Madrigal Pharmaceuticals | $4,293.34 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $890.72 | 2019 | |
| Abbott Laboratories | $230.88 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $207.55 | 2019-2022 | |
| Radius Health, INC. | $134.80 | 2019 | |
| Insulet Corporation | $118.93 | 2022 | |
| Amgen INC. | $103.39 | 2019-2025 | Repatha |
| Mannkind Corporation | $59.40 | 2023 | Afrezza |
| Becton, Dickinson and Company | $38.26 | 2019 | |
| Companion Medical, INC. | $33.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Disha Narang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.